Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467374 · ClinicalTrials.gov registry record · NA
Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder
A NA study of Obsessive - Compulsive Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT02467374: Completed NA study of Obsessive - Compulsive Disorder, sponsored by Massachusetts General Hospital.
NCT02467374 is a NA study of Obsessive - Compulsive Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 54 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02467374, a NA study of Obsessive - Compulsive Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out more about how the brain stores emotional learning in obsessive-compulsive disorder (OCD). In particular, we would like to understand how human beings learn not to fear. We are also interested in learning about how behavioral therapy (BT) for OCD affects emotional learning in the brain. We hope this study will help us understand why people with OCD cannot control unwanted fear and to develop better treatments for adults with OCD. Patients will be randomly assigned (like the flip of a coin) to receive 12 weeks of BT or 12 weeks of waitlist, followed by 12 weeks of BT. We are seeking individuals 18-60 with OCD and individuals with no psychiatric history. Participation includes a diagnostic evaluation, 12 weeks of BT or 12 weeks of waitlist followed by BT, questionnaires, and up to six (6) MRI scans. You may receive up to $500 for your participation and reimbursement for parking.
Primary Outcome
We assesed reduction in OCD symptom severity over a 24 week period. Efficacy was again compared in the follow-up phase of the study in from week 24 to week 36.
Conditions Studied
Interventions
- BEHAVIORAL Behavior Therapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-07-22 |
| Phase | NA |
What the finished NCT02467374 record still lists
NCT02467374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Behavior Therapy is the first listed.
NCT02467374 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02467374 about?
NCT02467374 is a clinical study titled "Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder". The purpose of this study is to find out more about how the brain stores emotional learning in obsessive-compulsive disorder (OCD). In particular, we would like to understand how human beings learn not to fear. We are also interested in learning about how behavioral therapy (BT) for OCD affects emot...
What is the current status of trial NCT02467374?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2014-12. Estimated completion is 2019-07-22.
What conditions does trial NCT02467374 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT02467374?
The interventions under investigation include: Behavior Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02467374?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02467374 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02467374's enrollment target sits among peer trials
54 41st of 84 higher than 44 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
-
Using Personalized Assessments in the Treatment of Childhood OCD
RECRUITING · NA
-
Neural Mechanisms of Response Inhibition Training for OCRD
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Interpretation Bias as a Mechanism of Treatment Response in OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia